Krystal Book Value Per Share from 2010 to 2025

KRYS Stock

USD 187.40 0.30 0.16%

Krystal Biotech Book Value Per Share yearly trend continues to be comparatively stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Krystal Biotech according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

33.09946838

Current Value

34.75

Quarterly Volatility

13.04153257

Credit Downgrade

Yuan Drop

Covid

Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 31.1 M, Interest Income of 31.1 M or Depreciation And Amortization of 7 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 4.5. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.

Check out the analysis of Krystal Biotech Correlation against competitors.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Latest Krystal Biotech's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Krystal Biotech over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Krystal Biotech's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 32.87 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Krystal Book Value Per Share Regression Statistics

	Arithmetic Mean	11.99
	Geometric Mean	1.62
	Coefficient Of Variation	108.75
	Mean Deviation	11.01
	Median	10.11
	Standard Deviation	13.04
	Sample Variance	170.08
	Range	34.6824
	R-Value	0.94
	Mean Square Error	21.17
	R-Squared	0.88
	Slope	2.58
	Total Sum of Squares	2,551

Krystal Book Value Per Share History

	2025	34.75
	2024	33.1
	2023	28.67
	2022	20.49
	2021	26.74
	2020	15.55
	2019	12.76

Other Fundumenentals of Krystal Biotech

Tangible Book Value Per Share

Krystal Biotech Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Property Plant Equipment	Net Invested Capital	Net Working Capital	Common Stock	Current Deferred Revenue	Long Term Investments
Total Assets		1.0	0.96	-0.91	-0.86	0.72	-0.72	0.97	0.94	1.0	0.97	0.93	0.93	-0.72	-0.2	0.91
Total Stockholder Equity	1.0		0.97	-0.92	-0.87	0.73	-0.7	0.98	0.93	1.0	0.97	0.93	0.94	-0.73	-0.19	0.9
Net Tangible Assets	0.96	0.97		-0.94	-0.91	0.85	-0.56	1.0	0.84	0.96	0.95	0.93	0.94	-0.82	-0.02	0.78
Net Debt	-0.91	-0.92	-0.94		0.79	-0.77	0.5	-0.93	-0.76	-0.93	-0.83	-0.9	-0.93	0.86	-0.06	-0.75
Retained Earnings	-0.86	-0.87	-0.91	0.79		-0.67	0.37	-0.92	-0.69	-0.85	-0.93	-0.89	-0.89	0.73	0.26	-0.59
Accounts Payable	0.72	0.73	0.85	-0.77	-0.67		-0.29	0.82	0.6	0.72	0.72	0.78	0.77	-0.67	0.43	0.59
Long Term Debt Total	-0.72	-0.7	-0.56	0.5	0.37	-0.29		-0.59	-0.89	-0.71	-0.65	-0.45	-0.45	0.29	0.35	-0.88
Capital Surpluse	0.97	0.98	1.0	-0.93	-0.92	0.82	-0.59		0.86	0.97	0.97	0.94	0.94	-0.8	-0.09	0.8
Total Liab	0.94	0.93	0.84	-0.76	-0.69	0.6	-0.89	0.86		0.93	0.89	0.8	0.8	-0.53	-0.31	0.97
Total Current Assets	1.0	1.0	0.96	-0.93	-0.85	0.72	-0.71	0.97	0.93		0.96	0.93	0.93	-0.75	-0.19	0.9
Property Plant Equipment	0.97	0.97	0.95	-0.83	-0.93	0.72	-0.65	0.97	0.89	0.96		0.92	0.91	-0.67	-0.25	0.84
Net Invested Capital	0.93	0.93	0.93	-0.9	-0.89	0.78	-0.45	0.94	0.8	0.93	0.92		1.0	-0.72	-0.12	0.77
Net Working Capital	0.93	0.94	0.94	-0.93	-0.89	0.77	-0.45	0.94	0.8	0.93	0.91	1.0		-0.76	-0.11	0.77
Common Stock	-0.72	-0.73	-0.82	0.86	0.73	-0.67	0.29	-0.8	-0.53	-0.75	-0.67	-0.72	-0.76		-0.04	-0.45
Current Deferred Revenue	-0.2	-0.19	-0.02	-0.06	0.26	0.43	0.35	-0.09	-0.31	-0.19	-0.25	-0.12	-0.11	-0.04		-0.19
Long Term Investments	0.91	0.9	0.78	-0.75	-0.59	0.59	-0.88	0.8	0.97	0.9	0.84	0.77	0.77	-0.45	-0.19

Click cells to compare fundamentals

About Krystal Biotech Financial Statements

Krystal Biotech shareholders use historical fundamental indicators, such as Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Book Value Per Share	33.10	34.75
Tangible Book Value Per Share	33.10	34.75

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC